The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review
Open accessAbstract
Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The AD pathophysiology entails chronic inflammation involving innate immune cells including microglia, astrocytes, and other peripheral blood cells. Inflammatory mediators such as cytokines and complements are also linked to AD pathogenesis. Despite increasing evidence supporting the association between abnormal inflammation and AD, no well-established inflammatory biomarkers are currently available for AD. Since many reports have shown that abnormal inflammation precedes the outbreak of the disease, non-invasive and readily available peripheral inflammatory biomarkers should be considered as possible biomarkers for early diagnosis of AD. In this minireview, we introduce the peripheral biomarker candidates related to abnormal inflammation in AD and discuss their possible molecular mechanisms. Furthermore, we also summarize the current state of inflammatory biomarker research in clinical practice and molecular diagnostics. We believe this review will provide new insights into biomarker candidates for the early diagnosis of AD with systemic relevance to inflammation during AD pathogenesis. [BMB Reports 2020; 53(1): 10-19].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Human nutrition, the gut microbiome and the immune system
Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., & Gordon, J. I. (2011) · Nature · doi:10.1038/nature10213 · Cited by 2,588
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“Activated microglia are one of the early hallmarks of AD pathogenesis (3).”
BackgroundBrain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“IL-1 levels are markedly overexpressed in the brains of patients with AD (26), mainly in microglia (26).”
BackgroundImmunoregulatory Feedback Between Interleukin-1 and Glucocorticoid Hormones
Besedovsky, H., del Rey, A., Sorkin, E., & Dinarello, C. A. (1986) · Science · doi:10.1126/science.3014662 · Cited by 1,519
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 14×
“IL-4 inhibits the secretion of IL-1, IL-6 and TNF- by activated monocytes (75).”
InfluentialIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“Numerous reports have shown over-activation of microglia (4, 5), activated complement system (6), increased production of cytokines (7) and chemokines during AD”
BackgroundSystemic infections and inflammation affect chronic neurodegeneration
Perry, V. H., Cunningham, C., & Holmes, C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2015 · Cited by 1,027
A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease
Baik, S. H., Kang, S., Lee, W., Choi, H., Chung, S., Kim, J.-I., & Mook-Jung, I. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.005 · Cited by 843
Self-citationBrain-Gut-Microbiota Axis in Alzheimer’s Disease
Kowalski, K., & Mulak, A. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18087 · Cited by 826
Cytokines and cognition–the case for a head-to-toe inflammatory paradigm.
Wilson, C. J., Finch, C. E., & Cohen, H. J. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50619.x · Cited by 637
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk
Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562
A neuromodulatory role of interleukin-1β in the hippocampus
Schneider, H., Pitossi, F., Balschun, D., Wagner, A., del Rey, A., & Besedovsky, H. O. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7778 · Cited by 498
Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., & Berger, M. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80737-n · Cited by 483
Bonfili, L., Cecarini, V., Berardi, S., Scarpona, S., Suchodolski, J. S., Nasuti, C., Fiorini, D., Boarelli, M. C., Rossi, G., & Eleuteri, A. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-02587-2 · Cited by 453
Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8657-1 · Cited by 447
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
Murray, C. A., & Lynch, M. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02974.1998 · Cited by 359
Tarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020568013953 · Cited by 349
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias
Tarkowski, E., Liljeroth, A.-M., Minthon, L., Tarkowski, A., Wallin, A., & Blennow, K. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00088-1 · Cited by 219
Huell, M., Strauss, S., Volk, B., Berger, M., & Bauer, J. (1995) · Acta Neuropathologica · doi:10.1007/bf00571510 · Cited by 214
Complement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184
Migration of neutrophils targeting amyloid plaques in Alzheimer's disease mouse model
Baik, S. H., Cha, M.-Y., Hyun, Y.-M., Cho, H., Hamza, B., Kim, D. K., Han, S.-H., Choi, H., Kim, K. H., Moon, M., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.003 · Cited by 181 · cited 2×
“migration of neutrophils traversing the BBB into the brain targeting amyloid plaques (10), recruitment of monocytes/ macrophages via CCL2 or CX3CL1 to the sites of inflammatory”
BackgroundSelf-citationAltered lymphocyte distribution in Alzheimer’s disease
RICHARTZSALZBURGER, E., BATRA, A., STRANSKY, E., LASKE, C., KOHLER, N., BARTELS, M., BUCHKREMER, G., & SCHOTT, K. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.010 · Cited by 167
Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., Pritchard, M., Tsolaki, M., Mecocci, P., Kloszewska, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064971 · Cited by 160
Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease
Alvarez, X. A., Franco, A., Fernández-Novoa, L., & Cacabelos, R. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815005 · Cited by 139
Interleukin‐1 in the Brain: Mechanisms of Action in Acute Neurodegeneration
PATEL, H. C., BOUTIN, H., & ALLAN, S. M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03136.x · Cited by 139
A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease
Naert, G., & Rivest, S. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt028 · Cited by 123
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Fonseca, M. I., Chu, S., Pierce, A. L., Brubaker, W. D., Hauhart, R. E., Mastroeni, D., Clarke, E. V., Rogers, J., Atkinson, J. P., & Tenner, A. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149792 · Cited by 87
Haure-Mirande, J.-V., Wang, M., Audrain, M., Fanutza, T., Kim, S. H., Heja, S., Readhead, B., Dudley, J. T., Blitzer, R. D., Schadt, E. E., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0255-6 · Cited by 84
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67 · cited 1×
“Specifically, it is characterized by neuroinflammation (1, 2).”
BackgroundSelf-citationWatanabe, Y., Kitamura, K., Nakamura, K., Sanpei, K., Wakasugi, M., Yokoseki, A., Onodera, O., Ikeuchi, T., Kuwano, R., Momotsu, T., et al. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000442585 · Cited by 65
Park, J.-C., Han, S.-H., Cho, H. J., Byun, M. S., Yi, D., Choe, Y. M., Kang, S., Jung, E. S., Won, S. J., Kim, E. H., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0248-8 · Cited by 63 · cited 1×
“combination of protease and phosphatase inhibitors has been used to detect low levels of blood biomarkers in AD (123).”
MethodSelf-citation
Cited by
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
Th17 cells and inflammation in neurological disorders: Possible mechanisms of action
Shi, Y., Wei, B., Li, L., Wang, B., & Sun, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932152 · Cited by 108
Rani, V., Verma, R., Kumar, K., & Chawla, R. (2023) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100149 · Cited by 93
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
Metadata
- Authors
- Park, J.-C., Han, S.-H., & Mook-Jung, I.
- Venue
- BMB Reports
- Published
- 2020-01-31
- Volume
- 53
- Issue
- 1
- Pages
- 10-19
- ISSN
- 1976-6696 (ISSN-L)
- 1976-670X
- OpenAlex
- W3000480166
- Cited by
- 201
- References
- 39
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.